Valneva distributes certain third-party vaccines in countries where it operates its own marketing and sales infrastructure. During the first quarter of 2025, third-party sales were €5.8 million ...

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...

An aide to U.S. Health Secretary Robert F. Kennedy Jr. is seeking more information about three vaccines recommended by a ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

Dr. Tedros Adhanom Ghebreyesus declares the end of the COVID-19 pandemic, highlighting global vaccination efforts and future ...

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Leerink Partnrs analysts have boosted Pfizer’s Q2 2025 earnings forecast from $0.52 to $0.57 per share, showing newfound ...